Anavex Life Sciences Corp (AVXL)

[McMagyar]

Why there is NO SHAME in ACCUMULATING SHARES
PART1
Let's start with Poster 1:


The MTD determination from the present Phase 2a study, allows for
a Phase 2/3 study to be conducted according to a double-blind
design including placebo. To complete the design of a future study,
population PK data (and the evaluation of inter-patient variability) are
necessary in order to compute the patients’ sample size and to
achieve conclusions associated with a given statistical power. This is
currently in progress.
• ANAVEX 2-73 may have a broader scope in addressing diseases by
virtue of both its molecular biology and the favorable safety profile
observed thus far. Estimating MTD is a prerequisite for the
progression of ANAVEX 2-73 towa
rds further clinical trial

the number of side benefits:
16 Events reported with the Preferred Term of ‘Therapeutic Response
Unexpected’. A sample of verbatim terms reported include:
ü Improved Engagement with Family/Friends
ü Improvement in Mood
ü Increased Independent Activity
ü Feeling Happier
ü Improved Alertness
ü Better Coordination
ü Better Coping

SAFETY:
96% of all AEs were mild or moderate and 83% events are
recovered/resolved. AE profile similar to that of healthy volunteer Phase
1 data (Schindler 2
So ACCUMULATE based on THIS if nothing else..